351 related articles for article (PubMed ID: 15817812)
21. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
[TBL] [Abstract][Full Text] [Related]
22. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids.
Popowski K; Eloranta JJ; Saborowski M; Fried M; Meier PJ; Kullak-Ublick GA
Mol Pharmacol; 2005 May; 67(5):1629-38. PubMed ID: 15692145
[TBL] [Abstract][Full Text] [Related]
23. Diet-induced obesity and hepatic gene expression alterations in C57BL/6J and ICAM-1-deficient mice.
Gregoire FM; Zhang Q; Smith SJ; Tong C; Ross D; Lopez H; West DB
Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E703-13. PubMed ID: 11832376
[TBL] [Abstract][Full Text] [Related]
24. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
Kast HR; Nguyen CM; Sinal CJ; Jones SA; Laffitte BA; Reue K; Gonzalez FJ; Willson TM; Edwards PA
Mol Endocrinol; 2001 Oct; 15(10):1720-8. PubMed ID: 11579204
[TBL] [Abstract][Full Text] [Related]
25. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.
Zhang S; Liu Q; Wang J; Harnish DC
Biochem Biophys Res Commun; 2009 Feb; 379(2):476-9. PubMed ID: 19118524
[TBL] [Abstract][Full Text] [Related]
26. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters.
Hoeke MO; Plass JR; Heegsma J; Geuken M; van Rijsbergen D; Baller JF; Kuipers F; Moshage H; Jansen PL; Faber KN
Hepatology; 2009 Jan; 49(1):151-9. PubMed ID: 19111018
[TBL] [Abstract][Full Text] [Related]
27. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
29. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids.
Chen W; Owsley E; Yang Y; Stroup D; Chiang JY
J Lipid Res; 2001 Sep; 42(9):1402-12. PubMed ID: 11518759
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
31. Regulation of carbohydrate metabolism by the farnesoid X receptor.
Stayrook KR; Bramlett KS; Savkur RS; Ficorilli J; Cook T; Christe ME; Michael LF; Burris TP
Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
[TBL] [Abstract][Full Text] [Related]
32. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
[TBL] [Abstract][Full Text] [Related]
33. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids.
Shih DM; Kast-Woelbern HR; Wong J; Xia YR; Edwards PA; Lusis AJ
J Lipid Res; 2006 Feb; 47(2):384-92. PubMed ID: 16269825
[TBL] [Abstract][Full Text] [Related]
34. The bile acid receptor FXR is a modulator of intestinal innate immunity.
Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
[TBL] [Abstract][Full Text] [Related]
35. Use of Saccharomyces cerevisiae in the identification of novel transcription factor DNA binding specificities.
Henry KW; Carey B; Howard WR; Hoefner D; Noonan DJ
Yeast; 2001 Mar; 18(5):445-54. PubMed ID: 11255252
[TBL] [Abstract][Full Text] [Related]
36. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression.
Song KH; Li T; Owsley E; Strom S; Chiang JY
Hepatology; 2009 Jan; 49(1):297-305. PubMed ID: 19085950
[TBL] [Abstract][Full Text] [Related]
37. Regulation of human liver delta-aminolevulinic acid synthase by bile acids.
Peyer AK; Jung D; Beer M; Gnerre C; Keogh A; Stroka D; Zavolan M; Meyer UA
Hepatology; 2007 Dec; 46(6):1960-70. PubMed ID: 17975826
[TBL] [Abstract][Full Text] [Related]
38. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
[TBL] [Abstract][Full Text] [Related]
39. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage.
Lian F; Xing X; Yuan G; Schäfer C; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP; Burgermeister E
Biochem J; 2011 Sep; 438(2):315-23. PubMed ID: 21619550
[TBL] [Abstract][Full Text] [Related]
40. Human kininogen gene is transactivated by the farnesoid X receptor.
Zhao A; Lew JL; Huang L; Yu J; Zhang T; Hrywna Y; Thompson JR; de Pedro N; Blevins RA; Peláez F; Wright SD; Cui J
J Biol Chem; 2003 Aug; 278(31):28765-70. PubMed ID: 12761213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
